AmorChem
Finance · Canada · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Westmount Square 1, Westmount, Quebec, H...Website
www.amorchem.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About AmorChem
AmorChem is a leading early stage venture fund focused on creating the next generation of biotech companies from academic research. Since its inception in 2011, it has financed over 30 research programs and established several biotech companies with innovative therapeutic approaches. The fund emphasizes the importance of translational research to bridge the innovation gap in the biotech sector. AmorChem aims to build a collaborative community of biotech start-ups in Canada, fostering a new generation of passionate science entrepreneurs.Explore more
AmorChem Org Chart
LT
Analyst
KH
Computational Chemist
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AmorChem your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at AmorChem
Earning: See what the market has to say on AmorChem recently announced quarterly report
Check out if AmorChem is spiking on competitors!
Click to see if AmorChem had a recent Job posting/layoffs
Check if AmorChem has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once AmorChem has new funding data
AmorChem, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when AmorChem launches new products
Recommended Actions
Reach out to Masked Content who joined AmorChem as Masked Content
Find more new buyers
Compare Similar Companies to AmorChem
Compare insights from companies similar to AmorChem, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
AmorChem is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
AmorChem is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about AmorChem.
AmorChem Tech Stack
A closer look at the technologies used by AmorChem
See more technologies
AmorChem News & Media
AmorChem Promotes Dr. Kevin McBride to General Partner
WESTMOUNT, Quebec--(BUSINESS WIRE)--It is with great pleasure that AmorChem announces the promotion of Kevin McBride to General Partner. With over 25 years of academic and biotech research experience, Kevin joined the team in 2012 and has been a dedicated contributor to the fund ever since. “Kevin brings a comprehensive understanding of fundamental and translational research which is a key component in setting portfolio strategy and lends him a credibility crucial to the attraction of partners,2021 Sweet Pharma Day Winner is HDAX Therapeutics!
MONTRÉAL--(BUSINESS WIRE)-- #biotech--AmorChem, BIOQuébec and CQDM, co-organizers of Sweet Pharma Day, are pleased to announce that HDAX Therapeutics is the winner of the 2021 edition. Sixteen Canadian startup companies (“Sweet 16”) selected by representatives from global pharma companies, made an elevator pitch in front of 150+ participants, who voted for HDAX Therapeutics as the winner of Sweet Pharma Day 2021 and of the $2,500 grand prize. This year, the digital event was under the sweetGiiant Pharma Inc Announced the Closing of US$11m in Seed Financing to Develop Its Precision Delivery Technology Platform in Gastroenterology
MONTREAL--(BUSINESS WIRE)-- #IBD--Giiant Pharma inc., a Montreal-based preclinical-stage biotech company, today announced the closing of US$11M (CAD$ 13.5M) million in Seed financing. The round was co-led by Amplitude Ventures and Genesys Capital, with participation from Fonds de solidarité FTQ, AmorChem II Fund, Theodorus Investment Funds, Anges Québec, and other angel investors. Giiant’s Precision Delivery technology platform originated from the work of former Merck Frosst scientists. The CompLiminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program For Eosinophilic-Driven Diseases
LAVAL, QC and CAMBRIDGE, England, July 17, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has acquired all of the issued and outstanding shares in the...
Read more news
Top Finance Companies
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding AmorChem
Sign Up For FreeTo access detailed company insights
AmorChem is a leading early stage venture fund focused on creating the next generation of biotech companies from academic research. Since its inception in 2011, it has financed over 30 research programs and established several biotech companies with innovative therapeutic approaches. The fund emphasizes the importance of translational research to b... Read More
